• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Amicus Therapeutics (NQ: FOLD )

    11.21 -0.23 (-2.01%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 28, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,598,798
    Open 11.32
    Bid (Size) 11.21 (1)
    Ask (Size) 11.88 (1)
    Prev. Close 11.44
    Today's Range 11.14 - 11.41
    52wk Range 9.020 - 14.57
    Shares Outstanding 266,555,274
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Beats Revenue for Q2 2024
    FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -21.28%
    -21.28%
    1 Month
    +10.88%
    +10.88%
    3 Month
    +19.76%
    +19.76%
    6 Month
    -13.44%
    -13.44%
    1 Year
    -13.17%
    -13.17%

    More News

    Read More
    Amicus Therapeutics to Announce Second Quarter 2024 Financial Results on August 8, 2024
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
    Via Benzinga
    The Analyst Landscape: 4 Takes On Amicus Therapeutics
    Via Benzinga
    Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today.
    Via Benzinga
    FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Stock Sees RS Rating Improve To 74
    Via Investor's Business Daily
    Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Stock Sees Improved Relative Strength Rating
    Via Investor's Business Daily
    Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Time to buy these 3 healthcare companies that raised revenue guidance?
    Via MarketBeat
    Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    7 Stocks Most Likely to Follow in WeWork’s Woeful Footsteps
    Via InvestorPlace
    Topics Bankruptcy
    Exposures Financial Legal
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.